MedTrace Logo

Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma

NCT04520165 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2024-10-04

Study results available
· View outcomes & findings →

Summary

The investigators will measure different cytokines in the sputum (interleukin ((IL))-3, granulocyte-macrophage colony-stimulating factor ((GM-CSF)), IL5, IL-13, IL-33, IL-4, IL-25 thymic stromal lymphopoietin ((TSLP)) and eotaxin-1 ) and in the blood to evaluate their ability to predict the response after 6 months and 1 year of treatment with a biologic treatment (anti-IgE, anti-IL5, anti-IL5R) in terms of reduction in exacerbations and corticosteroid use, improvement in Forced expiratory volume in the first second (FEV1) (+200ml), in asthma control (ACQ decrease \>0.5, ACT increase \>3), in asthma quality of life (increase in AQLQ score \> 0.5) and the effect on sputum and blood inflammation.

Conditions

Sponsors & Collaborators

  • University of Liege

    lead OTHER

Principal Investigators

  • Florence Schleich · Centre Hospitalier Universitaire de Liege

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2023-01-26
Completion
2025-08-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04520165 on ClinicalTrials.gov